P-31 NMR-SPECTRA OF EXTREMITY SARCOMAS - DIVERSITY OF METABOLIC PROFILES AND CHANGES IN RESPONSE TO CHEMOTHERAPY

被引:34
作者
KOUTCHER, JA
BALLON, D
GRAHAM, M
HEALEY, JH
CASPER, ES
HEELAN, R
GERWECK, LE
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT SURG,NEW YORK,NY 10021
[3] MEM SLOAN KETTERING CANC CTR,DEPT MED IMAGING,NEW YORK,NY 10021
[4] MASSACHUSETTS GEN HOSP,DEPT RADIAT MED,BOSTON,MA 02114
关键词
D O I
10.1002/mrm.1910160104
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We have used 31P NMR spectroscopy to study 22 patients with suspected sarcomas prior to any treatment. The spectra are characterized by the same peaks noted in murine tumors. The mean pH was 7.14 ± 0.08 and PCr/Pi was 1.18 ± 0.83. Comparison of pH and PCr/Pi, ratios in human and a murine tumor with a low hypoxic cell fraction revealed no significant differences. Six patients subsequently received chemotherapy and three responded to therapy (based on pathologic examination and/or tumor reduction greater than 50%). The three responding patients were noted to have significantly lower PDE/ PME in their pretreatment spectra than the three nonresponding patients. The three responding patients with sarcomas also showed a rise of > 100% in PDE/PME during the first cycle of therapy. Two of the responding patients had an increase of 0.37 pH units during this interval, which was not detected in the nonresponding patients. These data suggest that 31P NMR spectroscopy may be a useful prognostic indicator in conjunction with other clinical parameters. © 1990 Academic Press, Inc. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:19 / 34
页数:16
相关论文
共 35 条